Healthcare / Drug Manufacturers - Specialty & GenericNasdaqCM
$2.02
-0.98 (-32.67%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-6.7M · quality 68.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-58.8%
↓Gross Margin
-311.8%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-23276.5%
FCF / Net income
0.79x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $17000.0 · net income $-5.0M · FCF $-4.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $17000.00 | $17000.00 | — | — | — |
| Net Income | $-5.0M | $-5.0M | $-14.6M | $-9.3M | $-8.8M |
| EBITDA | $-4.3M | $-4.3M | $-14.7M | $-9.6M | $-8.9M |
| EPS | — | — | -105.52 | -122.94 | -317.30 |
| Gross Margin | -311.8% | -311.8% | — | — | — |
| Operating Margin | -30129.4% | -30129.4% | — | — | — |
| Net Margin | -29541.2% | -29541.2% | — | — | — |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.02 | 0.01 | — |
| Current Ratio | 1.78 | 1.78 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.0M | $-4.0M | $-12.6M | $-6.7M | $-6.5M |
| Returns | |||||
| ROE | -58.8% | -58.8% | -799.8% | -129.1% | -79.8% |
| Valuation | |||||
| P/B | 0.10 | 0.10 | 1.26 | 0.78 | 0.34 |
| Growth & Yield | |||||
| EPS Growth | — | — | 14.2% | 61.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-79.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-105.52 → n/d
Residual
-79.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.